Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, has announced it will host a corporate update webinar on September 2, 2026, at 4 p.m. EDT. The webinar will feature founder, President and CEO Maria Maccecchini, Ph.D., and will include a live question-and-answer session. The event is expected to provide stakeholders with insights into the company's recent progress, ongoing clinical programs, and upcoming milestones.
The announcement comes at a critical time for Annovis, as the company prepares to report top-line data from its fully enrolled pivotal Phase 3 Alzheimer's disease (AD) trial, with regulatory submissions anticipated in 2027. According to the company, this trial is evaluating buntanetap, an investigational oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, buntanetap aims to halt disease progression and improve cognitive and motor functions in patients.
In addition to the Phase 3 AD trial, Annovis plans to initiate an AD open-label study in October 2026 to generate long-term safety data. The company's Parkinson's disease (PD) open-label study is already underway, and discussions continue regarding the initiation of a Parkinson's disease dementia program. These efforts underscore Annovis's commitment to expanding its pipeline and addressing the significant unmet needs in neurodegenerative diseases.
The webinar is a key opportunity for investors and the medical community to gain a deeper understanding of Annovis's clinical strategy and the potential impact of buntanetap. With Alzheimer's and Parkinson's diseases affecting millions worldwide, the development of disease-modifying therapies is of paramount importance. Annovis's focus on targeting multiple toxic proteins simultaneously could offer a novel approach that differentiates it from other treatments in development.
Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to improving the lives of patients suffering from neurodegenerative diseases. The company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that has shown promise in preclinical and clinical studies. As the company advances its clinical programs, the upcoming webinar will serve as a platform to communicate progress and future direction to stakeholders.
For more information about the webinar and Annovis's pipeline, interested parties can visit the company's website at https://www.annovisbio.com. The full press release is available at https://ibn.fm/mls3F. Additionally, the latest news and updates relating to ANVS can be found in the company's newsroom at https://ibn.fm/ANVS.
